Restricted accessOtherFirst published online 1995-12
Does determination of tissue platinum levels by mass spectroscopy have potential for monitoring exposure of pharmacy personnel to platinum-based antineoplastic drugs? A pilot study
The mutagenic and carcinogenic properties of cyto toxic drugs have led to concern over potential haz ards to pharmacy personnel who are required to prepare cytotoxic drugs. The platinum compounds cisplatin and carboplatin are frequently used antican cer agents and are unique by virtue of their suitability for quantification by highly sensitive physical meth ods such as inductively coupled plasma mass spec troscopy (ICPMS). We have performed a pilot study of ICPMS determination of platinum levels in biological samples from pharmacists preparing chemotherapy, including platinum-based antineoplastic drugs. In pa tients treated with platinum compounds, elemental platinum was readily detected in plasma and whole leukocytes and bound to leukocyte DNA for at least 4 weeks after treatment. However, in 28 pharmacists from our institution (18 involved in preparation of platinum-based compounds, 10 controls), tissue plat inum levels were below the limit of detection (0.05 nmol/L) by ICPMS. ICPMS measurement of platinum levels has the potential to be used to monitor health care workers for exposure to platinum-based cytotox ics. Exposure may result from accidental exposure to a platinum-based compound or may be due to poor technique by personnel preparing chemotherapy doses. We are intending to institute a prospective monitoring policy to gather further data.
Rodriquez P. , Yap CYAbnormal blood results found in pharmacists preparing cytotoxics [Letter]. Aust JHosp Pharm. 1991;21:39.
2.
McDiarmid M. , Egan T.Acute occupational exposure to antineoplastic agents. J Occup Med.1988;30: 984-987.
3.
Hemminki K., Kyyronen P., Lindbohm MLSpontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Commun Health. 1985;39:141-147.
4.
Selevan SG, Lindbohn ML, Hornung RW, et al. A study of occupational exposure to antineoplastic drugs and foetal loss in nurses. N Engl J Med.1985;313:1173-1178.
5.
Saurel-Cubizolles MJ, Job-Spira N., Estryn-Behar M.Ectopic pregnancy and occupational exposure to antineoplastic drugs. Lancet. 1993;341:1169-1171.
6.
Norppa H., Sorsa M., Vainio H.Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health . 1986;6:299-301.
7.
Ferguson LR, Everts R., Robbie MA, et al. The use within New Zealand of cytogenetic approaches to monitoring of hospital pharmacists for exposure to cytotoxic drugs: report of a pilot study in Auckland. Aust J Hosp Pharm.1988 ;18:228-233.
8.
Cooke J., Williams J., Morgan RJ, et al. Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm.1991;48:1199-1205.
9.
Ferguson LR, Everts R., McKinnon HM, et al. Monitoring of drug absorption by pharmacists and oncology nurses in four New Zealand hospitals using estimation of cytokinesis-blocked micronuclei: a follow-up study in Auckland. Aust JHosp Pharm. 1990;20:212-217.
10.
Elliot G., Ferguson L., Everts R., et al. Monitoring mutagenicity in urine and peripheral blood lymphocytes of pharmacists occupationally exposed to anticancer drugs. NZ Med J. 1990;103:13-16.
11.
Venitt S., Crofton-Sleigh C., Hunt J., et al. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorption . Lancet. 1984;1: 74-77.
12.
Guidelines for the handling of cytotoxic drugs and related waste in health care establishments. Work Cover Authority of New South Wales. October 1993.
13.
SHPA Guidelines for the Safe Handling of Cytotoxic Drugs in Pharmacy Departments. Aust J Hosp Pharm.1990 ;20:391-394.
14.
SHPA Guidelines for the Transportation and Handling of Cytotoxic Drugs by Lay Personnel. Aust J Hosp Pharm.1988;18:355-391.
15.
SHPA Guidelines for the Packaging of Cytotoxic Agents. Aust J Hosp Pharm.1986;16:156.
16.
Sessink Pjm , Anzion RB, Van den Broek Phh, et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department . Pharm Weebl (Sci). 1992;14:16-22.
17.
Van Raalte J , Rice C., Moss CEVisible-light system for detecting doxorubicin contamination on skin and surfaces. Am J Hosp Pharm.1990;47:1067-1074.
18.
Dixon T.Location of cytotoxic drug spillages using ultraviolet light. Aust JHosp Pharm. 1990;20:469- 470.
19.
McDiarmid M. , Egan T., Furio M., et al. Sampling for airborne fluorouracil in a hospital drug preparation area. Am J Hosp Pharm.1986;43:1942-1945.
20.
McDevitt JJ , Lees Psj, McDiarmid MAExposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med.1993 ;35:57-60.
21.
Staiano N., Gallelli JF, Adamson RH, et al. Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. Lancet. 1981;1: 615-616.
22.
McDiarmid M.Medical surveillance for anti-neoplastic drug handlers. Am J Hosp Pharm.1990;47:1061-1066.
23.
Reed E., Kohn KWCisplatin and platinum analogs. In: Chabner BA, Collins J, eds. Cancer Chemotherapy-Principles & Practice. Philadelphia : Lippincott; 1990.
24.
Hennings H., Shores RA, Poirer MC, et al. Enhanced malignant conversion of benign mouse skin tumors by cisplatin. J Natl Cancer Inst. 1990;82:836 - 840.
25.
International Agency for Research on Cancer.Some Antineoplastic and Immunosuppressive Agents. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans . World Health Organization. 1981 ;26:159.
26.
Leopold WR, Miller EC, Miller JACarcinogenicity of antitumour cis-platinum (II) coordination complexes in the mouse and rat. Cancer Res.1979;39: 913-918.
27.
Reed E., Yuspa SH, Zwelling LA, et al. Quantification of cis-diamminedichloroplatinum II (cisplatin)-DNAintrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy . J Clin Invest.1986;77:545-550.
28.
Cleanrooms and clean workstations. Part 2: Laminar flow cleanrooms . Australian Standard 1386.2-1989.
29.
Laminar flow cytotoxic drug safety cabinets-installation and use. Australian Standard 2639-1994.
30.
Cleanrooms and clean workstations. Part 6: Operation and inspection of cleanrooms. Australian Standard 1386.6- 1989.
31.
Department of Pharmacy Policy and Procedures Manual, Westmead Hospital and Community Health Services, 1993. Chapter 11, Sterile products-IV Admixtures and Cytotoxic Drug Services.
32.
Maniatis T, Fritsch EF, Sambrook J, eds. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbour Laboratory Press; 1989.
33.
Yamasaki E. , Ames BNConcentrations of mutagens from urine by absorption with the non-polar resin XAD-2: cigarette smokers have mutagenic urine. Proc Natl Acad Sci USA. 1977;74:3555-3559.
34.
Box RP, Theuws Jlg, Henderson PTExcretion of mutagens in urine after passive smoking. Cancer Lett.1983;19:85-90.
35.
Baker R., Arlaukas A., Bonin A., et al. Detection of mutagenic activity in human urine following fried pork or bacon meals. Cancer Lett.1982;16:81- 89.
36.
Guinee EP, Beuman GH, Hageman G., et al. Evaluation of genotoxic risk of handling cytostatic drugs in clinical pharmacy practice. Pharm Weekbl (Sci). 1991;13:78-82.
37.
Mason B.Principles of Geochemistry. 2nd ed. New York: Wiley; 1958.
38.
Bradford CWPlatinum. In: Seiler HG, Sigel H, eds. Handbook on Toxicity of Inorganic Compounds. New York: Marcel Dekker ; 1988:533-539.
39.
Ensslin AS, Pethran A., Schierl R., et al. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994;65: 339-342.
40.
Hodge VF, Stallard MOPlatinum and palladium in roadside dust. Environ Sci Technol.1986;20:1058-1060.
41.
Messerschmidt J., Alt F., Tolg G., et al. Adsorptive voltametric procedure for the determination of platinum baseline levels in the human body. Fresenius JAnal Chem.1992;343:391-394.
42.
Nygren O., Vaughan GT, Florence TM, et al. Determination of platinum in blood by adsorptive voltametry . Anal Chem.1990;62:1637-1640.
43.
Vaughan GT, Florence TMPlatinum in the human diet, blood, hair and excreta. Sci Total Environ. 1992;111:47-58.
44.
Tilby MJ, Johnson C., Knox RJ, et al. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res.1991;51:123-129.
45.
Poirer MC, Lippard SJ, Zwelling LAAntibodies elicited against cis-diamminedichloro-platinum (II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci U S A1982 ;79:6443- 6447.
46.
Fichtiner-Schepman Amj, Baan RA, Berends F.Influence of the degree of DNA modification of the immunochemical determination of cisplatin-DNA adduct levels. Carcinogenesis (Lond) 1989;10:2367-2369.
